“Wednesday's 31,444 new local COVID-19 infections broke a record set on April 13, when the commercial hub of Shanghai was crippled by a city-wide lockdown of its 25 million residents that would last two months.”
From Geert: “I continue to emphasize that in highly vaccinated countries Bird Flu may start to spread asymptomatically via vaccinees and that C-19 unvaccinated who vaccinate against seasonal/common Flu are at high risk of contracting Ab-dependent enhancement of avian Flu disease!”
“A South African laboratory study using Covid-19 samples from an immunosupressed individual over six months showed that the virus evolved to become more pathogenic, indicating that a new variant could cause more illness than the current predominant omicron strain.”
From Geert: “These non-talents do not realize that what they are considering ‘absolution of antigenic sin’ is nothing else than immune refocusing. The latter occurs upon vaccine breakthrough infection, which explains why these vaccines are not protective against productive infection and disease but only against severe disease and death! What these pseudo-vaccinologists don’t say (or don’t know?) is that ‘immune refocusing-enabling breakthrough infections’ only provide short-lived protection and drive immune escape. Hence, if implemented at large scale, these vaccines will eventually drive co-circulation of highly infectious variants (in the same way that we’re currently observing with Omicron descendants). I am predicting with 200 % certainty that co- circulation of highly infectious variants paves the way to enhanced viral virulence in vaccinees. These professors should study the immune epidemiology of viruses chased by mass vaccination rather than continuing the eternal cycle of empiricism which has been the biggest shortcoming in vaccinology all along!”
“Although absolute rates of myocarditis were low, vaccine type, age and sex are important factors to consider when strategizing vaccine administration to reduce the risk of postvaccination myocarditis. Our findings support the preferential use of the BNT162b2 vaccine over the mRNA-1273 vaccine for people aged 18–29 years.”
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.